Cardiff Oncology, Inc. develops clinical-stage cancer therapies centered on PLK1 inhibition and its lead oral inhibitor onvansertib. Company news commonly covers onvansertib in RAS-mutated metastatic colorectal cancer, including the CRDF-004 Phase 2 program evaluating combinations with standard-of-care regimens such as FOLFIRI/bevacizumab and FOLFOX/bevacizumab.
Updates also include preclinical and investigator-initiated work in other oncology settings, including metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, HER2-low breast cancer models and chronic myelomonocytic leukemia. Corporate releases also address oncology conference presentations, key opinion leader events, executive appointments, investor conferences and Nasdaq inducement equity grants.
Cardiff Oncology (CRDF) received FDA Fast Track designation for onvansertib combined with FOLFIRI/bevacizumab as a first-line treatment for metastatic colorectal cancer. The designation covers adults with KRAS- or NRAS-mutated disease and is supported by the ongoing randomized Phase 2 CRDF-004 trial.
The proposed Phase 3 regimen, 30 mg onvansertib plus FOLFIRI/bevacizumab, achieved a 72.2% confirmed objective response rate, versus 42.1% with FOLFIRI/bevacizumab alone, in the intent-to-treat population. As of September 28, 2026, median progression-free survival had not been reached in the 30 mg arm, versus approximately 11 months in the combined standard-of-care arms. All patients remaining in the 30 mg arm have now received treatment for at least 21 months. Cardiff plans a registrational trial intended to support approval. Onvansertib also received FDA Orphan Drug Designations for two other cancers in October and November 2026.
Cardiff Oncology (CRDF) reported a narrower third-quarter net loss while its Phase 2 colorectal cancer trial remained ongoing. Net loss was $8.857 million versus $11.258 million a year earlier; loss per share was $0.12 versus $0.17.
Median progression-free survival, or time without disease worsening, was not reached in the 30 mg onvansertib plus FOLFIRI/bevacizumab arm, versus approximately 11 months in the combined standard-of-care arms. Patients remaining in that onvansertib arm had received treatment for at least 21 months. Cardiff expects a Phase 3 start in Q1 2027, subject to additional financing.
Cash, cash equivalents and short-term investments totaled approximately $33.8 million at September 30. Cardiff expects these resources to fund operations through the end of Q3 2027. Nine-month operating cash use increased to approximately $33.9 million from $31.9 million.
Cardiff Oncology (CRDF) management will present and participate in investor meetings at the UBS Global Biopharma Conference on November 16–17, 2026. President and CEO Mani Mohindru will lead a fireside chat on November 16 at 2:40 PM GMT. A live webcast will be accessible through the company website’s Events section, with a replay available after the presentation.
Cardiff Oncology (CRDF) appointed Leila Alland as interim Chief Medical Officer, succeeding Roger Sidhu, who stepped down from the role.
The randomized Phase 2 trial in first-line RAS-mutated metastatic colorectal cancer remains ongoing. Median progression-free survival, the time before cancer worsens or death, has not been reached in the onvansertib 30 mg plus FOLFIRI and bevacizumab arm, the proposed Phase 3 regimen. All patients remaining on trial have been on treatment for more than 18 months. Cardiff plans to initiate its registrational Phase 3 study in the first quarter of 2027. Alland previously served as Chief Medical Officer at PMV Pharma, Affimed and Tarveda Therapeutics.
Cardiff Oncology (Nasdaq: CRDF) received FDA Orphan Drug Designation for onvansertib to treat patients with chronic myelomonocytic leukemia (CMML).
Onvansertib is being evaluated in a Phase 1 investigator-initiated study in relapsed/refractory CMML. Results presented at the 2025 American Society of Hematology Annual Meeting described relatively good tolerability as monotherapy and preliminary efficacy in approximately 40% of myeloproliferative CMML patients. Three patients experienced clinical benefits (38%), including platelet, white blood cell and spleen responses. One patient (12.5%) had an optimal marrow response, with bone marrow blasts falling from 8% to 2%, facilitating a stem cell transplant; three patients had stable disease (38%).
Designation benefits may include tax credits, certain FDA fee exemptions and up to seven years of market exclusivity upon regulatory approval. The designation does not change approval requirements.
Cardiff Oncology (CRDF) and Nerviano Medical Sciences have amended their 2017 Exclusive License Agreement for onvansertib, resolving all outstanding disputes and litigation between the parties.
The companies reached a settlement that includes a full, mutual release of all claims in the case pending in the U.S. District Court for the Southern District of California and plan to jointly request dismissal of all claims with prejudice. The Amendment clarifies and expands the royalty structure, sets development objectives tied to Cardiff’s upcoming Phase 3 program in first-line RAS-mutated metastatic colorectal cancer, and grants NMS rights to appoint a Board observer and to join Cardiff’s Scientific Advisory Board, formalizing an expanded collaboration around onvansertib’s global clinical development.
Cardiff Oncology (CRDF) will participate in two conferences in September 2026 featuring Mani Mohindru, Ph.D. The company will present at the 8th Annual RAS-Targeted Drug Development Summit on Tuesday, September 8 at 9:00 AM ET, discussing PLK1-targeted therapy in RAS mutant metastatic colorectal cancer, and at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14 at 10:00 AM ET for a fireside chat. Slides and, for H.C. Wainwright, a live webcast and replay will be available via the “Events” section of the Cardiff Oncology website.
Summary not available.
Cardiff Oncology (Nasdaq: CRDF) entered into definitive agreements for a registered direct offering of 8,571,429 common shares with accompanying warrants to purchase up to 8,571,429 shares at a purchase price of $1.05 per share plus warrant. Certain officers and directors will separately purchase 731,707 shares and warrants at $1.435 per share plus warrant.
The warrants will have an exercise price of $1.31, become exercisable six months after issuance and following an increase in authorized common shares after stockholder approval, and will expire five and a half years from initial exercise. Closing is expected on or about July 16, 2026, with anticipated gross proceeds of approximately $10 million before fees. According to Cardiff Oncology, net proceeds are intended for working capital and general corporate purposes. H.C. Wainwright & Co. is acting as exclusive placement agent, and the securities are issued under an effective SEC shelf registration.
Cardiff Oncology (Nasdaq: CRDF) reported positive Phase 2 results for onvansertib in first-line RAS‑mutated metastatic colorectal cancer. The 30 mg onvansertib + FOLFIRI/bevacizumab arm achieved a confirmed ORR of 72.2% vs 42.1% for standard FOLFIRI/bevacizumab, with median PFS not yet reached and a favorable safety profile. A randomized Phase 3 registrational trial of onvansertib 30 mg + FOLFIRI/bevacizumab vs standard-of-care is planned following an End‑of‑Phase 2 FDA meeting. An investor webcast is scheduled for June 3, 2026.